CA2989884A1 - Compositions and methods for treating lung diseases and lung injury - Google Patents

Compositions and methods for treating lung diseases and lung injury Download PDF

Info

Publication number
CA2989884A1
CA2989884A1 CA2989884A CA2989884A CA2989884A1 CA 2989884 A1 CA2989884 A1 CA 2989884A1 CA 2989884 A CA2989884 A CA 2989884A CA 2989884 A CA2989884 A CA 2989884A CA 2989884 A1 CA2989884 A1 CA 2989884A1
Authority
CA
Canada
Prior art keywords
composition
mol
lipid
present
rnai
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2989884A
Other languages
English (en)
French (fr)
Inventor
Kuan-Ju CHEN
Franziska LEIFER
Vladimir Malinin
Walter Perkins
Jimin Zhang
Keith DIPETRILLO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of CA2989884A1 publication Critical patent/CA2989884A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2989884A 2015-07-09 2016-07-11 Compositions and methods for treating lung diseases and lung injury Abandoned CA2989884A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190583P 2015-07-09 2015-07-09
US62/190,583 2015-07-09
PCT/US2016/041776 WO2017008076A1 (en) 2015-07-09 2016-07-11 Compositions and methods for treating lung diseases and lung injury

Publications (1)

Publication Number Publication Date
CA2989884A1 true CA2989884A1 (en) 2017-01-12

Family

ID=57686097

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2989884A Abandoned CA2989884A1 (en) 2015-07-09 2016-07-11 Compositions and methods for treating lung diseases and lung injury

Country Status (7)

Country Link
US (1) US20180200186A1 (enExample)
EP (1) EP3319976B1 (enExample)
JP (1) JP6884714B2 (enExample)
AU (2) AU2016291228B2 (enExample)
CA (1) CA2989884A1 (enExample)
ES (1) ES2898340T3 (enExample)
WO (1) WO2017008076A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
US9469600B2 (en) 2013-10-25 2016-10-18 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
MX384843B (es) 2014-05-15 2025-03-14 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3787602A4 (en) 2018-05-02 2022-03-23 Insmed Incorporated PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS
JP2021532098A (ja) 2018-07-19 2021-11-25 インペル ニューロファーマ インコーポレイテッド パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達
GB2606038B (en) * 2018-09-04 2023-05-03 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
CN109432047B (zh) * 2018-10-29 2021-07-20 中国药科大学 一种逆转肺纤维化纳米制剂及其制备方法
CN119632930A (zh) 2019-04-29 2025-03-18 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
US20230013636A1 (en) * 2019-12-05 2023-01-19 Board Of Regents, The University Of Texas System Exosomes-based therapy for liver fibrosis and other diseases with fibrosis
US12115230B2 (en) 2020-04-09 2024-10-15 Verve Therapeutics, Inc. Base editing of ANGPTL3 and methods of using same for treatment of disease
MX2023000511A (es) * 2020-07-10 2023-02-13 Genevant Sciences Gmbh Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones.
WO2022060871A1 (en) 2020-09-15 2022-03-24 Verve Therapeutics, Inc. Lipid formulations for gene editing
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
MX2023011227A (es) 2021-03-22 2023-12-06 Recode Therapeutics Inc Composiciones y metodos para administracion dirigida a celulas.
CN113058042B (zh) * 2021-04-01 2023-06-30 易慧生物技术(上海)有限公司 一种可鼻喷的稳定递载rna分子的脂质纳米颗粒制备方法
CN115245559B (zh) * 2021-04-25 2026-05-01 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
JP2024520834A (ja) 2021-06-09 2024-05-24 レコード・セラピューティクス・インコーポレイテッド ポリヌクレオチド組成物、関連する製剤及びその使用方法
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2023019192A1 (en) * 2021-08-11 2023-02-16 Board Of Regents, The University Of Texas System Dry liposome formulations and related methods thereof
PL249473B1 (pl) * 2021-08-14 2026-04-27 Bs Biotechna Spolka Z Ograniczona Odpowiedzialnoscia Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie jako nośnika leku oraz w terapii genowej i sposób ładowania liposomu emetyną
EP4226949A1 (en) * 2022-02-14 2023-08-16 Pantherna Therapeutics GmbH Preparation for use in a method for the treatment and/or prevention of a disease
WO2024242216A1 (ko) * 2023-05-23 2024-11-28 주식회사 케이더블유바이오 대식세포 표적화 리포좀 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
KR20060036119A (ko) * 2003-08-20 2006-04-27 가부시키가이샤 로코모젠 시노비올린 활성 조절 작용의 검출 방법
US20060134189A1 (en) * 2004-11-17 2006-06-22 Protiva Biotherapeutics, Inc siRNA silencing of apolipoprotein B
AU2009303345B2 (en) * 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2011108955A1 (en) * 2010-03-03 2011-09-09 Universidade De Coimbra Multi -targeting system comprising a nanocarrier, nucleic acid(s) and non-nucleic acid based drug(s)
EP3456827A3 (en) * 2010-06-02 2019-05-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
US20140308304A1 (en) * 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
US20150246137A1 (en) * 2012-09-27 2015-09-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof

Also Published As

Publication number Publication date
WO2017008076A1 (en) 2017-01-12
JP6884714B2 (ja) 2021-06-09
JP2018519818A (ja) 2018-07-26
AU2020203367A1 (en) 2020-06-11
EP3319976A4 (en) 2019-03-20
EP3319976B1 (en) 2021-09-01
ES2898340T3 (es) 2022-03-07
US20180200186A1 (en) 2018-07-19
EP3319976A1 (en) 2018-05-16
AU2016291228A1 (en) 2017-12-07
AU2016291228B2 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
AU2016291228B2 (en) Compositions and methods for treating lung diseases and lung injury
CN101346393B (zh) 修饰的siRNA分子及其应用
TWI658830B (zh) Ｈｓｐ47表現調控強化用類視色素脂質體
US20080076701A1 (en) Dicer substrate rna peptide conjugates and methods for rna therapeutics
US20070293449A1 (en) Compositions and methods for delivery of double-stranded rna
JP2024541993A (ja) Ｒｎａコンストラクト及びその使用
JP2008504827A (ja) 免疫賦活性ｓｉＲＮＡ分子およびその使用方法
JP2023534206A (ja) 肺に治療薬を送達するための脂質ナノ粒子
JP2024534066A (ja) 脂質ナノ粒子製剤
EP4041400B1 (en) Messenger rnas encoding sting and il-12 and use in the treatment of cancer
US20260109727A1 (en) Rna constructs and uses thereof
JP2021518345A (ja) 喘息またはアレルギー性疾患を処置するための方法
KR102931885B1 (ko) 대식세포 유래 소포로 코팅된 지질 나노입자 및 이의 제조 방법
WO2024026257A2 (en) Engineered polynucleotides for cell selective expression
US20170253879A1 (en) APTAMER-RNAi THERAPEUTIC COMPOSITIONS
WO2023240225A1 (en) Constitutively active polymeric sting mimics for antitumor immunity
JP2023039115A (ja) 物質送達キャリア及び組成物
JP5872898B2 (ja) 標的遺伝子の発現を抑制する組成物
WO2012098692A1 (ja) 標的遺伝子の発現を抑制する組成物
WO2025149492A1 (en) Rna encoding an immune inhibitory il-1 family member

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210706

FZDE Discontinued

Effective date: 20240109